Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atralin Gel 0.05% for Erythematotelangiectatic Rosacea
NCT01125930Phase 3Terminated
- Start
- May 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tretinoin in Erythematotelangiectatic Rosacea (ETR). Primary endpoint: Severity of Erythematotelangiectatic Rosacea Signs: Redness (Non Transient Erythema) at 24 weeks. Started May 2010; status: terminated.
02
Drugs
tretinoin
03
Conditions
Erythematotelangiectatic Rosacea (ETR)
Beyond the preview
Go deeper on NCT01125930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125930.